Experimental mRNA therapy for hard-to-treat autoimmune disease
Part of Immune system & allergy clinical trials.
This study tests a new kind of treatment called LNP-mRNA that targets specific cells involved in autoimmune diseases like lupus. It might help reset your immune system if standard treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with an autoimmune disease (like lupus) that has come back or hasn't improved with standard treatment.
- You are able to take care of yourself (KPS score above 60) and your doctor expects you to live at least 6 more months.
- You are willing to use reliable birth control during the study and for 30 days after the last dose (if you could become pregnant).
- You do not have other uncontrolled cancers, serious heart disease, or certain infections (like active hepatitis B or C, HIV, or syphilis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new mRNA treatment that targets CD19, a protein on some immune cells that cause autoimmune diseases. It aims to help people with severe or treatment-resistant autoimmune diseases like immune thrombocytopenia, autoimmune hemolytic anemia, lupus, or scleroderma, where the immune system attacks the body's own tissues.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This study tests a new mRNA-based medicine that targets CD19 on cancer cells. It is for people with B-cell lymphoma or leukemia who have run out of standard treatment options.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.